Omalizumab versus cyclosporin-A for the treatment of chronic spontaneous urticaria: can we define better-responding endotypes?

Kocaturk E., BÜLBÜL BAŞKAN E., SU KÜÇÜK Ö., Ozdemir M., Ornek S., Can P. K., ...Daha Fazla

ANAIS BRASILEIROS DE DERMATOLOGIA, cilt.97, sa.5, ss.592-600, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 97 Sayı: 5
  • Basım Tarihi: 2022
  • Doi Numarası: 10.1016/j.abd.2022.03.003
  • Dergi Adı: ANAIS BRASILEIROS DE DERMATOLOGIA
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database, Directory of Open Access Journals
  • Sayfa Sayıları: ss.592-600
  • Anahtar Kelimeler: Biomarker, Chronic urticaria, Cyclosporine, Omalizumab, BIOMARKERS
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Background: Chronic Spontaneous Urticaria (CSU) is characterized by recurrent wheals and/or angioedema for longer than 6-weeks. Guidelines recommend Omalizumab (Oma) as first-line and Cyclosporine-A (Cs-A) as second-line treatment in antihistamine resistant CSU. This step-wise algorithm might be time-consuming and costly.